Highbridge Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Highbridge Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-32,245	Closed	-$5.01M	–	1656
2017 Q2	$5.01M	Buy	32,245 +9,245	+40%	+$1.41M	0.07%	296
2017 Q1	$3.34M	Buy	+23,000	New	+$3M	0.05%	363
2016 Q4	–	Sell	-2,709	Closed	-$329K	–	1430
2016 Q3	$329K	Buy	+2,709	New	+$365K	0.01%	977
2016 Q1	–	Sell	-7,670	Closed	-$1.08M	–	1638
2015 Q4	$1.08M	Buy	+7,670	New	+$1.06M	0.02%	724
2015 Q3	–	Sell	-2,476	Closed	-$436K	–	1689
2015 Q2	$436K	Sell	2,476 -14,576	-85%	-$2.62M	0.01%	1018
2015 Q1	$2.95M	Buy	+17,052	New	+$2.93M	0.04%	443
2014 Q2	–	Sell	-2,703	Closed	-$375K	–	1179
2014 Q1	$375K	Buy	+2,703	New	+$407K	﹤0.01%	781

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Highbridge Capital Management's JAZZ Position: Q3 2017 in Review

Highbridge Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 32,245 shares — an estimated $5.01M sold.

Highbridge Capital Management first reported a position in JAZZ in Q1 2014 and held it in 7 quarters. The position peaked at $5.01M in Q2 2017. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

Highbridge Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 32,245 Jazz Pharmaceuticals shares in Q3 2017, an estimated $5.01M.
Highbridge Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Highbridge Capital Management's Jazz Pharmaceuticals position peaked at $5.01M in Q2 2017.
303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.